Progenics Pharma (PGNX) Misses Q1 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. DOX
4. AMGN
5. DUOL
6. ANET
7. SWKS
8. CVS
9. SPY
10. XYZ

Go back to Progenics Pharma (PGNX) Misses Q1 EPS by 5c

Progenics Pharmaceuticals Announces First Quarter 2016 Financial and Business Results

May 5, 2016 7:31 AM EDT

On May 2nd, the Company Announced It Had Granted Exclusive World-Wide Rights to Bayer to Develop and Commercialize Products Using Progenics PSMA Antibody Technology In Combination with Alpha-Emitting RadionuclidesEnrollment in Pivotal Phase 3 Study of PSMA-Targeted SPECT/CT Imaging Agent 1404 Ongoing in the U.S. and CanadaPyL Study Data to be Presented at the 2016 American Urological AssociationAZEDRA® Pivotal Phase 2b Trial Topline Results Expected Between December 2016 and March 2017On  April 4th, Oral RELISTOR® PDUFA Date Was Set for July 19, 2016; Approval to Trigger $50 Million Milestone Payment from Valeant plus Royalties and Sales... More